Lakefront Biotherapeutics (LKFT) Free Cash Flow (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Free Cash Flow for 12 consecutive years, with -$107.5 million the latest figure, recorded in Q1 2026.

• Quarterly Free Cash Flow fell 149.36% year-over-year to -$107.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215.7 million (down 21.78% YoY) and the FY2025 annual result came in at -$366.0 million, up 25.89% from the prior year.
• Free Cash Flow advanced to -$107.5 million in Q1 2026 per LKFT's latest filing, from -$116.1 million in the prior quarter.
• Over the last five years, Free Cash Flow for LKFT reached as high as $4.8 million in Q3 2024 and fell as low as -$258.4 million in Q4 2022.
• A 5-year average of -$85.7 million and a median of -$105.6 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2025 — Free Cash Flow jumped 71.07% — and 2026, when it plunged 149.36%.
• Year by year, Free Cash Flow stood at -$258.4 million in 2022, then surged by 42.48% to -$148.6 million in 2023, then gained by 4.07% to -$142.6 million in 2024, then grew by 18.56% to -$116.1 million in 2025, then advanced by 7.39% to -$107.5 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$107.5 million, -$116.1 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.